Abstract YO31
Case summary
A 66-year-old male presented with left-sided pleuritic chest pain, common weak for 2 months and progressively increasing shortness of breath with dry cough for 1.5 months.On general survey, mild pallor was present, but there were no clubbing and palpable cervical and axillary lymph node. An X-ray showed a shadow in the left chest. The shadow of the heart was shifted to the right. Bronchoscopy showed compression of segmental bronchus of the left upper lobe bronchus. CT of the chest reveals a nodular pleura-based mass, which size was about 12.5х18.0х18.0 sm with effusion in the left pleural cavity. Around the nodular pleura-based mass were infiltrative changens. The histological analysis of tru-cut biopsy showed that there was fibrotic mesothelioma with necrosis or carcinoid. The patient underwent right upper lobectomy of lung with negative margins. During operation we saw that half of left pleural cavity was occupied by gigantic tumor, which size was 25x20x18 sm. Surface was bumpy, it had capsule, thick texture. There were effusion (150ml) in the left pleural cavity. The root of the lung, pericardium, thoracic part of aorta, diaphragm were free. The tumor was grew from right upper lobe (S5). The histological analysis after operation of this tumor showed that it was round cell sarcoma. After surgery, six cycles of adjuvant chemotherapy with ifosfamide and doxorubicin were given. Postadjuvant chemotherapy patient is kept on regular follow-up.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract